Journal
TRANSFUSION AND APHERESIS SCIENCE
Volume 60, Issue 3, Pages -Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.transci.2021.103104
Keywords
Rituximab; Convalescent plasma; COVID-19; Hypogammaglobulinemia
Categories
Ask authors/readers for more resources
The use of convalescent plasma therapy in lymphoma patients with low gammaglobulin levels showed effectiveness in treating relapsed COVID-19, leading to clinical improvement and reducing the risk of virus relapse.
Patients with haematological malignancies are considered to be a risk group for developing severe Coronavirus disease (Covid-19). Because of the limitations of therapeutic options, the development of new treatment strategies is mandatory, such as convalescent plasma (CP). Herein we report the use of CP therapy as an off-label indication in two lymphoma patients with relapsed COVID-19 in the setting of low gammaglobulin levels because of previous rituximab chemo-immunotherapy. Both were PCR positive for SARS-CoV-2 but had an absence of antibodies to the virus more than one month later of symptoms initiation. They developed important respiratory and neurological complications. After CP infusion, neutralising antibodies were detected and viral load dissapeared in both patients leading to clinical improvement with no more Covid-19 relapse.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available